GlaxoSmithKline

10,498

$40.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.35 (+0.87%) Today
$0.00 (0.00%) As of 7:43 AM EDT after-hours

Why Robinhood?

You can buy or sell GSK and other stocks, options, ETFs, and crypto commission-free!

About GSK

GlaxoSmithKline plc, also called GlaxoSmithKline, is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). Read More The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Employees
99,437
Headquarters
Middlesex, Greater London
Founded
1999
Market Cap
101.35B
Price-Earnings Ratio
16.86
Dividend Yield
4.86
Average Volume
2.55M
High Today
$40.79
Low Today
$40.38
Open Price
$40.58
Volume
2.25M
52 Week High
$48.25
52 Week Low
$31.43

Collections

GSK News

Financial PostJul 7

Glaxo and Medicago Team Up on Plant-Based Covid Vaccine

(Bloomberg) — GlaxoSmithKline Plc is collaborating on an experimental Covid-19 vaccine with Medicago, a biotechnology company partly owned by tobacco giant Phil
0
ReutersJul 7

GSK, Philip Morris venture tie-up for potential COVID-19 shot

FILE PHOTO: General view outside GlaxoSmithKline (GSK) headquarters in Brentford, following the outbreak of the coronavirus disease (COVID-19), London, Britain,
0
ReutersJul 7

BRIEF-GSK And Medicago To Collaborate On Developing Novel Adjuvanted Covid-19 Candidate Vaccine

July 7 (Reuters) - GlaxoSmithKline PLC: * GSK AND MEDICAGO ANNOUNCE COLLABORATION TO DEVELOP A NOVEL ADJUVANTED COVID-19 CANDIDATE VACCINE * COLLABORATION COM
0

GSK Earnings

$0.00
$0.24
$0.49
$0.73
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
— per share
Actual
Available Jul 29

You May Also Like

More GSK News

Financial TimesJul 6

GSK’s anti-HIV drug better at preventing infection, trial finds

A GlaxoSmithKline anti-HIV drug given every two months is significantly better at preventing infection than the current standard of care, an international trial
0
ReutersJul 5

Britain nears $625 million Sanofi/GSK COVID-19 vaccine deal: report

LONDON (Reuters) - Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-
0
New York TimesJul 5

Britain Nears 500 Million Sterling Supply Deal for Sanofi/GSK COVID-19 Vaccine-Sunday Times

LONDON — Britain is close to agreeing a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of their potential COV
0
New York TimesJul 2

U.S. FDA Approves GSK's HIV Drug for Patients With Limited Options

(Reuters) - The U.S. Food and Drug Administration on Thursday approved GlaxoSmithKline Plc's HIV drug, Rukobia, to treat adult patients who have run out of trea
0
ReutersJul 2

GSK says it is within weeks of resubmitting HIV injection Cabenuva

A GSK logo is seen on a flag at a GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls/Files FRANKFURT (Reuter
0
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.